Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026)
Gilead Sciences' (GILD) quarterly Goodwill & Intangibles came in at $24.7 billion in Q1 2026, down 10.74% YoY from $27.7 billion in Q1 2025, and down 2.36% on a QoQ basis from $25.3 billion in Q4 2025.
Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Goodwill & Intangibles data on file, last reported at $24.7 billion in Q1 2026.
- Quarterly Goodwill & Intangibles fell 10.74% year-over-year to $24.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 billion (down 10.74% YoY) and the FY2025 annual result came in at $25.3 billion, down 10.51% from the prior year.
- Goodwill & Intangibles retreated to $24.7 billion in Q1 2026, from $25.3 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $38.6 billion in Q1 2022 to a low of $24.7 billion in Q1 2026.
- A 5-year average of $32.1 billion and a median of $31.7 billion in 2024 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2023 — Goodwill & Intangibles decreased 5.13% — and 2024, when it declined 18.71%.
- Tracing GILD's Goodwill & Intangibles over 5 years: stood at $37.2 billion in 2022, then declined by 6.56% to $34.8 billion in 2023, then decreased by 18.71% to $28.3 billion in 2024, then decreased by 10.51% to $25.3 billion in 2025, then decreased by 2.36% to $24.7 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $24.7 billion (Q1 2026), $25.3 billion (Q4 2025), and $26.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.35 Bn |
| Mar 31, 2026 | 24.70 Bn |
| Dec 31, 2025 | 25.29 Bn |
| Sep 30, 2025 | 26.28 Bn |
| Jun 30, 2025 | 26.88 Bn |
| Mar 31, 2025 | 27.67 Bn |
| Dec 31, 2024 | 28.26 Bn |
| Sep 30, 2024 | 28.86 Bn |
| Jun 30, 2024 | 31.15 Bn |
| Mar 31, 2024 | 31.74 Bn |
| Dec 31, 2023 | 34.77 Bn |
| Sep 30, 2023 | 35.47 Bn |
| Jun 30, 2023 | 36.06 Bn |
| Mar 31, 2023 | 36.66 Bn |
| Dec 31, 2022 | 37.21 Bn |
| Sep 30, 2022 | 37.75 Bn |
| Jun 30, 2022 | 38.20 Bn |
| Mar 31, 2022 | 38.65 Bn |
| Dec 31, 2021 | 41.79 Bn |
| Sep 30, 2021 | 42.23 Bn |